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The Oral Strategy trial [1] studied patients with active rheumatoid arthritis (RA). They had all 
responded inadequately to methotrexate, the dominant conventional disease modifying drug 
(DMARD). The key comparison in the trial was the effects of combining different treatments 
with methotrexate. One treatment was tofacitinib. This is an orally active Janus Kinase (JAK) 
inhibitor, a relatively new type of drug for RA. The other treatment was adalimumab an 
established injectable tumour necrosis factor inhibitor biologic therapy for RA. Over 12 months 
both combined treatments improved disease activity by similar amounts. Their adverse events 
were comparable.  
 
The non-inferiority head-to-head design used in the Oral Strategy trial is growing in popularity. 
It avoids using inactive placebos. Several recent RA trials had this design [2-4]. Establishing 
non-inferiority has complexities. Large sample sizes are usually needed. The trial evaluates 
whether the confidence interval of the difference between treatments falls within the non-
inferiority margin of the primary outcome. The non-inferiority margin is defined before 
patients enter the trial. In the Oral Strategy trial the primary outcome ± ACR50 responses ± 
signifies clinically important improvements. An appropriately narrow non-inferiority margin 
was used. The proportion of patients achieving ACR50 responses was numerically greatest 
with tofacitinib-methotrexate. Secondary outcomes were similar. Its conclusion tofacitinib-
methotrexate combinations are non-inferior to adalimumab-methotrexate is robust. 
 
The Oral Strategy Trial and other studies [5,6] show tofacitinib is effective in RA without major 
toxicity concerns. It will have a role in some active RA patients. Another oral JAK inhibitors 
is currently available for active RA. This is baricitinib, which has comparable efficacy and side 
effect levels [4]. The merits of one of these JAK inhibitor over the other are uncertain. But 
patients and clinicians benefit when there are choices between effective oral drugs. Although 
combining JAK inhibitors with methotrexate is likely to be the way they are generally used in 
clinical practice, monotherapy gives clinical and functional responses as shown in the Oral 
Strategy trial; it may be appropriate in some patients. The clinical use of these JAK inhibitors 
will reflect two things. First their risks and benefits in routine practice settings. Second 
KHDOWKFDUHIXQGHUV¶YLHZVabout what is affordable.  
 
Assessing risks and benefits in routine clinical practice is difficult. When biologics were 
introduced there were substantial uncertainties about their risks. Consequently large 
prospective registers of treated RA patients were established. Together with trials these 
registers showed biologics increased serious infections. However, the balance of risks and 
benefits were judged acceptable for patients with severe RA. Oral JAK inhibitors also increase 
serious infections. This risk is shown in the Oral Strategy trial. Caution is therefore needed 
when JAK inhibitors are used routinely. Reassuringly, a systematic review of serious adverse 
events in 117 RA trials found no specific concerns with tofacitinib [7].  
 
International recommendations vary on the optimal treatment of active RA after inadequate 
responses to methotrexate. American experts [8] outline several different strategies: combining 
traditional DMARDs; adding a biologic; or adding an oral JAK kinase inhibitor. They carefully 
avoid expressing any preferences. A Cochrane meta-analysis [9] took a different view. The 
authors suggested preferentially combining conventional DMARDs as triple therapy 
(methotrexate, sulfasalazine and hydroxychloroquine). Their justification was the balance of 
efficacies and costs. European experts [10] recommend assessing prognostic factors like 
autoantibodies. When there are no factors associated with a poor prognosis more conventional 
DMARDs are suggested. In patients with poor prognoses adding a biologic or oral JAK kinase 
inhibitor are suggested, with current practice being to give biologics. One key limitation with 
the intensive use of conventional DMARDs, including triple therapy, is that trials and 
observational studies show these combinations are often discontinued over 6-12 months [3,11]. 
To control active RA some patients are bound to need injectable biologics or oral JAK 
inhibitors.  
 
Costs were not evaluated in the Oral Strategy trial. Yet they will have crucial roles determining 
JAK inhibitor use. Biologics for severe, active RA fall within, or above, the upper limits of 
acceptable cost-effectiveness [12]. JAK inhibitors will only be used to any extent if their cost-
effectiveness is comparable or better. When treatments have similar efficacy and risks, 
healthcare funders expect the preferential use of the least expensive option. JAK inhibitors will 
only be used substantially if their cost is comparable to biosimilars.  
 
The Oral Strategy trial highlighted three benefits from the combination of tofacitinib and 
methotrexate in active RA. First its efficacy and toxicity are comparable to injectable biologics 
like adalimumab. Second its onset of action seems equally rapid, Third most patients are able 
to remain on tofacitinib therapy for 12 months. These findings are extremely encouraging. They 
show the ongoing benefits of innovation in drug treatment. The trial also underlines the major 
flaw of all intensive treatment regimens in active RA patients who failed to respond to 
methotrexate. Only a minority of patients achieve remission with any treatment strategy. While 
effective RA treatments have expanded greatly in recent years its overall management still has 
substantial room for improvement. 
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